Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis
- PMID: 7836713
- DOI: 10.1016/s0168-8278(05)80323-x
Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis
Abstract
The effects of octreotide on postprandial hemodynamic responses were evaluated in 20 patients with postnecrotic cirrhosis. They were randomly assigned to receive either a 100-micrograms bolus with a 100-micrograms/h infusion of octreotide or a placebo. Placebo administration did not affect any of the hemodynamic values. However, after a liquid meal of 500 kcal, postprandial increases in the hepatic venous pressure gradient and hepatic blood flow were observed in patients receiving placebo, while the systemic hemodynamic values remained unchanged. In contrast, in patients receiving octreotide, the hepatic blood flow was significantly decreased 30 min after administration, while the hepatic venous pressure gradient and the systemic hemodynamic values were not affected. After ingestion of a meal, the mean values of the hepatic blood flows were not significantly different from basal values. Moreover, the wedged hepatic venous pressure, the hepatic venous pressure gradient and the systemic hemodynamic values were not affected by meal ingestion. However, during octreotide infusion, hepatic blood flow 30 min after the meal had a tendency to increase compared to before the meal. In conclusion, octreotide inhibited the postprandial increase in portal pressure in patients with postnecrotic cirrhosis. In addition, octreotide decreased hepatic blood flow in the fasting state. When given before a meal, the increase in blood flow induced by the meal restored the hepatic blood flow to basal levels.
Similar articles
-
Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis.Scand J Gastroenterol. 2002 Apr;37(4):482-7. doi: 10.1080/003655202317316132. Scand J Gastroenterol. 2002. PMID: 11989841 Clinical Trial.
-
Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.J Hepatol. 1994 Jul;21(1):88-94. doi: 10.1016/s0168-8278(94)80142-8. J Hepatol. 1994. PMID: 7963427 Clinical Trial.
-
Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.Gastroenterology. 1992 Jul;103(1):229-34. doi: 10.1016/0016-5085(92)91117-m. Gastroenterology. 1992. PMID: 1612330
-
Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis.Am J Gastroenterol. 1999 Apr;94(4):1012-7. doi: 10.1111/j.1572-0241.1999.01005.x. Am J Gastroenterol. 1999. PMID: 10201475 Clinical Trial.
-
Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease.Aliment Pharmacol Ther. 2001 Jun;15(6):857-64. doi: 10.1046/j.1365-2036.2001.00996.x. Aliment Pharmacol Ther. 2001. PMID: 11380324 Clinical Trial.
Cited by
-
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 6;4(4):CD013121. doi: 10.1002/14651858.CD013121.pub2. Cochrane Database Syst Rev. 2021. PMID: 33822357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical